This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
4 Best Value Stocks With Low PEG to Boost Your Portfolio Returns
by Urmimala Biswas
Here are four PEG-driven value stocks that fit our screening criteria: JD, UHS, FMS, and QFIN.
HCI Group and Boise Cascade have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
HCI Group and Boise Cascade have been highlighted as Zacks Bull and Bear of the Day.
Zacks.com featured highlights JD.com, City Office REIT, Fresenius Medical Care, Itron and Enersys
by Zacks Equity Research
JD.com, City Office REIT, Fresenius Medical Care, Itron and Enersys have been highlighted in this Screen of The Week article.
DaVita Stock Declines 1.2% in 3 Months: Here's How to Play
by Debanjana Dey
DVA's stable core business and global expansion are offset by rising labor costs and declining commercial mix, creating a mixed outlook for investors.
3 Undervalued MedTech Stocks to Buy for 2025 Gains Amid S&P 500 Rally
by Urmimala Biswas
Three discounted MedTech stocks to gain from the market rebound are PAHC, FMS and INMD.
5 Low Price-to-Book Stocks to Include in Your Portfolio for Gains
by Kinjel Shah
The P/B ratio helps to identify low-priced stocks with high growth prospects. JD, CIO, FMS, ITRI and ENS are some such stocks.
4 Value Picks That Could Weather Tariff Volatility and Slowing Growth
by Sumit Singh
Value investing is essentially about selecting stocks that are usually cheap but fundamentally sound. FMS, ENS, GM & ITRI boast a low P/CF ratio.
Is Fresenius Medical Care AG & Co. (FMS) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
4 Top PEG Stocks Based on GARP Approach to Smart Investing
by Urmimala Biswas
Here are four discounted PEG stocks, JAZZ, FMS, DAN and ITRI, which qualify our screening criteria.
Zacks.com featured highlights Fresenius Medical Care, Deutsche Telekom and Hanover Insurance
by Zacks Equity Research
Fresenius Medical Care, Deutsche Telekom and Hanover Insurance have been highlighted in this Screen of The Week article.
3 Stocks Trading Near 52-Week High With Room to Rise Further
by Vasundhara Sawalka
Investors target stocks that have been on a bullish run lately. Stocks like FMS, DTEGY and THG are seeing price strength and the momentum is likely to continue.
Best Momentum Stock to Buy for March 18th
by Zacks Equity Research
ASLE, FMS and TEF made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on March 18, 2025.
Why Fresenius (FMS) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Fresenius (FMS) is a Strong Value Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Is Alignment Healthcare (ALHC) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Alignment Healthcare (ALHC) and Fresenius (FMS) have performed compared to their sector so far this year.
FMS Stock Gains Following Stake Sale to Reduce Debt & Boost Profit
by Zacks Equity Research
Fresenius Medical Care's parent company sells 10.6 million shares, the proceeds of which will be used to reduce its leverage and achieve higher profits in 2025.
Should Value Investors Buy Fresenius Medical Care AG & Co. (FMS) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Top 3 Medical Instruments Industry Stocks to Ride the GenAI Boom
by Urmimala Biswas
FMS, MASI and VCYT from the Zacks Medical Instruments industry are worth buying based on genAI adoption, strategic developments and strong fundamentals. Yet, geopolitical complications and wage and supply issues mar the prospects.
Fresenius Medical Q4 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
FMS' fourth-quarter results showcase a strong segmental performance along with providing full year 2025 outlook for revenue growth and operating income.
Why Fresenius (FMS) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
The Zacks Analyst Blog Highlights Fresenius Medical, Masimo, Merit Medical Systems and Inogen
by Zacks Equity Research
Fresenius Medical, Masimo, Merit Medical Systems and Inogen are included in this Analyst Blog.
What to Expect From These 4 Medical Device Stocks in Q4 Earnings?
by Indrajit Bandyopadhyay
Here is a sneak peek into how four Medical Device stocks, namely FMS, MASI, MMSI and INGN, are expected to fare in their quarterly results, slated to be released tomorrow.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks Value Investor Highlights: Alaska Air, Heidrick & Struggles, USANA Health Sciences, General Motors and Fresenius Medical Care
by Zacks Equity Research
Alaska Air, Heidrick & Struggles, USANA Health Sciences, General Motors and Fresenius Medical Care have been highlighted in this Value Investor article.
5 Classic Value Stocks for 2025
by Tracey Ryniec
These stocks are cheap and have top Zacks Ranks of Strong Buy or Buy.